Our Team

• NIH-NCI Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Predoctoral MD/PhD Degree Fellows (F30‑CA250248, 2020 – 2024)
• NIH-NCI Oncogenesis & Developmental Biology Training Grant (T32‑CA080621, 2018 – 2019)
• NIH Medical Scientist Training Program Training Grant (T32‑GM008152, 2016 – 2017)
• Phi Beta Kappa, 2012
• University of Oregon Dean’s Scholarship & Dean’s List (2008 – 2012)
• University of Oregon Freshman Scholarship (2008 – 2009)

• Chalmers ZR, Roberts HJ, Wo JY. T3N0 Rectal Cancer: Radiation for All, None, or Some? The Cancer Journal. 30(4): p232-237, 7/8 2024.

• Pendergrast T, Chalmers ZR. Anki Tagger: A Generative AI Tool for Aligning Third-Party Resources to Pre-clinical Curriculum. JMIR Medical Education. 2023;9:e48780.

• Rodriguez Y, Unno K, Truica MI, Chalmers ZR, Yoo YA, Vatapalli R, Sagar V, Yu J, Lysy B, Hussain M, Han H, Abdulkadir SA. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. Cancer Research. 2022 Jun 6;82(11):2110-2123.

• Fenton SE, Chalmers ZR, Hussain M. PARP Inhibition in Advanced Prostate Cancer. The Cancer Journal. 2021 Nov-Dec 01;27(6):457-464.

• Chalmers ZR, Burns MC, Ebot EM, Frampton GM, Ross JS, Hussain MHA, Abdulkadir SA. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions. Prostate Cancer. 2021 Jun;24(2):558-566.

• Unno K, Chalmers ZR, Pamarthy S, Vatapalli R, Rodriguez Y, Lysy B, Mok H, Sagar V, Han H, Yoo YA, Ku SY, Beltran H, Zhao Y, Abdulkadir SA. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer. Cancer Research. 2021 Apr 15;81(8):2157-2170.

• Koga Y, Song H, Chalmers ZR, Newberg J, Kim E, Carrot-Zhang J, Piou D, Polak P, Abdulkadir SA, Ziv E, Meyerson M, Frampton GM, Campbell JD, Huang FW. Genomic Profiling of Prostate Cancers from Men with African and European Ancestry. Clinical Cancer Research. 2020 Sep 1;26(17):4651-4660.

• Vatapalli R, Sagar V, Rodriguez Y, Zhao JC, Unno K, Pamarthy S, Lysy B, Anker J, Han H, Yoo YA, Truica M, Chalmers ZR, Giles F, Yu J, Chakravarti D, Carneiro B, Abdulkadir SA. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nature Communications. 2020 Aug 19;11(1):4153.

• Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, Sagar V, Luan Y, Chalmers ZR, Unno K, Mok H, Vatapalli R, Yoo YA, Rodriguez Y, Kandela I, Parker JB, Chakravarti D, Mishra RK, Schiltz GE, Abdulkadir SA. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Cancer Cell. 2019 Nov 11;36(5):483-497.

• Chalmers ZR, Johnson A, Ali SM, Frampton GM, Miller V, Ross JS, Pal SK. Comprehensive Genomic Profiling of Renal Cell Carcinoma at Initial Diagnosis and Putative Local Recurrence. European Urology Focus. 2018 Mar;4(2):267-269.

• Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Hsu S, Lesser GJ, Stogner-Underwood K, Mott RT, Rush SZ, Stanke JJ, Dahiya S, Sun J, Reddy P, Chalmers ZR, Erlich R, Chudnovsky Y, Fabrizio D, Schrock AB, Ali S, Miller V, Stephens PJ, Ross J, Crawford JR, Ramkissoon SH. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. The Oncologist. 2017 Dec;22(12):1478-1490.

• Goetz MP, Suman VJ, Reid JM, Northfelt DW, Mahr MA, Ralya AT, Kuffel M, Buhrow SA, Safgren SL, McGovern RM, Black J, Dockter T, Haddad T, Erlichman C, Adjei AA, Visscher D, Chalmers ZR, Frampton G, Kipp BR, Liu MC, Hawse JR, Doroshow JH, Collins JM, Streicher H, Ames MM, Ingle JN. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women with Endocrine-Refractory Metastatic Breast Cancer. Journal of Clinical Oncology. 2017 Oct 20;35(30):3391-3400.

• Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, Huang F, He Y, Sun J, Tabori U, Kennedy M, Lieber DS, Roels S, White J, Otto GA, Ross JS, Garraway L, Miller VA, Stephens PJ, Frampton GM. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine. 2017 Apr 19;9(1):34.

• Sperger JM, Strotman LN, Welsh A, Casavant BP, Chalmers Z, Horn S, Heninger E, Thiede SM, Tokar J, Gibbs BK, Guckenberger DJ, Carmichael L, Dehm SM, Stephens PJ, Beebe DJ, Berry SM, Lang JM. Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation. Clinical Cancer Research. 2017 Feb;23(3):746-756

• Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunology Research. 2016 Nov;4(11):959-967.

• Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. Journal of Thoracic Oncology. 2016 Sep;11(9):1493-502.

• Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discovery. 2015 Aug;5(8):850-9.

• Ou SH, Chalmers ZR, Azada MC, Ross JS, Stephens PJ, Ali SM, Miller VA. Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. Lung Cancer. 2015 Jun;88(3):352-4.

• Chalmers ZR, Ali SM, Ohgami RS, Campregher PV, Frampton GM, Yelensky R, Elvin JA, Palma NA, Erlich R, Vergilio JA, Chmielecki J, Ross JS, Stephens PJ, Hermann R, Miller VA, Miles CR. Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy. Blood Cancer Journal. 2015 Feb 6;5:e278.

• Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, Elvin J, Ali SM, Ross JS, Basturk O, Balasubramanian S, Lipson D, Yelensky R, Pao W, Miller VA, Klimstra DS, Stephens PJ. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discovery. 2014 Dec;4(12):1398-405.

Abstracts

• Chalmers ZR, Frampton GM, Ross JS, Hussain MH, Abdulkadir SA. “Age-related variation in gene alteration frequency in metastatic prostate cancer.” Poster Presentation at ASCO GU Annual Meeting. February 2019.

• Chalmers ZR, Huang FW, Gay LM, Ali SM, Chmielecki J, Ross JS, Miller VA, Ganesan S, Stephens P, Garraway LA, Frampton GM. “Analysis of tumor mutation burden (TMB) in >51,000 clinical cancer patients to identify novel non-coding PMS2 promoter mutations associated with increased TMB.” Poster Presentation at ASCO Annual Meeting. June 2016.

• Chalmers ZR, Huang FW, Gay LM, Ali SM, Yelensky R, Chmielecki J, Ross JS, Miller VA, Stephens PJ, Garraway LA, Frampton GM. “Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load.” Poster Presentation at AACR Annual Meeting. April 2016.

• Chalmers ZR, Chmielecki J, Elvin JA, Vergilio JA, Suh J, Ramkissoon SH, Frampton G, Miller VA, Stephens PJ, Ross JS. “Pangenomic analysis of BRAF genomic alterations across all types of brain tumors reveals expanded opportunities for targeted therapies.” Poster Presentation at USCAP Annual Meeting. March 2016.

• Chalmers ZR, Ali SM, Frampton GM, Chmielecki J, Palma NA, Elvin JA, Johnson A, Yelensky R, Ross JS, Stephens PJ, Miller VA. “Comprehensive genomic profiling (CGP) of pediatric gliomas reveals a high frequency of clinically relevant genomic alterations (CRGA) associated with benefit from targeted therapy.” Poster Presentation at SNO Biennial Pediatric Meeting. May 2015.

• Chalmers Z, Ali S, Elvin J, Lipson D, Wang K, Yelensky R, Chmielecki J, Fichtenholz A, Frampton G, Miller V, Stephens P. “Comprehensive genomic profiling of brain glioblastoma reveals frequent clinically relevant genomic alterations.” Oral Presentation at USCAP Annual Meeting. March 2015.

• Chalmers ZR. “Real math: bringing proof into the classroom.” Oral presentation at University of Oregon Undergraduate Research Symposium, May 2012.

Posters

• Chalmers ZR, Frampton GM, Ross JS, Hussain MH, Abdulkadir SA. “Age-related variation in gene alteration frequency in metastatic prostate cancer.” Poster Presentation at ASCO GU Annual Meeting. February 2019.

• Chalmers ZR, Huang FW, Gay LM, Ali SM, Chmielecki J, Ross JS, Miller VA, Ganesan S, Stephens P, Garraway LA, Frampton GM. “Analysis of tumor mutation burden (TMB) in >51,000 clinical cancer patients to identify novel non-coding PMS2 promoter mutations associated with increased TMB.” Poster Presentation at ASCO Annual Meeting. June 2016.

• Chalmers ZR, Huang FW, Gay LM, Ali SM, Yelensky R, Chmielecki J, Ross JS, Miller VA, Stephens PJ, Garraway LA, Frampton GM. “Broad analysis of recurrent somatic mutations in cancer reveals a common novel non-coding mutation in the promoter of PMS2 associated with greatly increased tumor mutation load.” Poster Presentation at AACR Annual Meeting. April 2016.

• Chalmers ZR, Chmielecki J, Elvin JA, Vergilio JA, Suh J, Ramkissoon SH, Frampton G, Miller VA, Stephens PJ, Ross JS. “Pangenomic analysis of BRAF genomic alterations across all types of brain tumors reveals expanded opportunities for targeted therapies.” Poster Presentation at USCAP Annual Meeting. March 2016.

• Chalmers ZR, Ali SM, Frampton GM, Chmielecki J, Palma NA, Elvin JA, Johnson A, Yelensky R, Ross JS, Stephens PJ, Miller VA. “Comprehensive genomic profiling (CGP) of pediatric gliomas reveals a high frequency of clinically relevant genomic alterations (CRGA) associated with benefit from targeted therapy.” Poster Presentation at SNO Biennial Pediatric Meeting. May 2015.